title: The Helicobacter felis mouse model in assessing anti-Helicobacter therapies and gastric mucosal prostaglandin E2 levels.
abstract: BACKGROUND
  The aims of the present study were to assess the usefulness of the Helicobacter felis mouse model in the evaluation of antimicrobial therapies and the effect of Helicobacter infection on gastric mucosal prostaglandin E2 release.
  
  
  METHODS
  Barrier-maintained BALB/c mice were infected with H. felis and treated with different antibacterial therapies. H. felis status was determined by bacterial culture, urease test, and bacterial and histologic stainings. Release of prostaglandin E2 from the gastric mucosa was measured by radioimmunoassay.
  
  
  RESULTS
  All triple-treated mice were cleared of bacteria both 24 h and 1 month after treatment. However, tinidazole alone also resulted in 100% eradication. Monotherapies with erythromycin acistrate, tetracycline, colloidal bismuth subcitrate, and nitecapone failed to eradicate the bacteria. The release of gastric prostaglandin E2 was doubled in the infected mice (554 +/- 39, mean +/- SE) compared with the noninfected mice (270 +/- 35) (p < 0.01).
  
  
  CONCLUSIONS
  The H. felis mouse model proved satisfactory for assessing both anti-Helicobacter therapies and the prostaglandin E2 release. The reliability of this method was improved when several methods to assess the H. felis status were used in parallel.
authors.affiliation: Research Unit of Alcohol Diseases, University of Helsinki, Finland.
authors.forename: J
authors.initials: J
authors.lastname: Höök-Nikanne
authors.forename: P
authors.initials: P
authors.lastname: Aho
authors.forename: P
authors.initials: P
authors.lastname: Kärkkäinen
authors.forename: T U
authors.initials: TU
authors.lastname: Kosunen
authors.forename: M
authors.initials: M
authors.lastname: Salaspuro
mesh_terms: D000658:Amoxicillin / Q000627:therapeutic use; D000818:Animals; D000897:Anti-Ulcer Agents / Q000627:therapeutic use; D002396:Catechols / Q000627:therapeutic use; D015232:Dinoprostone / Q000378:metabolism*; D004195:Disease Models, Animal; D004359:Drug Therapy, Combination; D004917:Erythromycin / Q000627:therapeutic use; D005753:Gastric Mucosa / Q000378:metabolism*; D016481:Helicobacter Infections / Q000188:drug therapy* / Q000378:metabolism*; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D009942:Organometallic Compounds / Q000008:administration & dosage; D010422:Pentanones / Q000627:therapeutic use; D013752:Tetracycline / Q000008:administration & dosage; D014011:Tinidazole / Q000008:administration & dosage
chemical_list: D000897:Anti-Ulcer Agents; D002396:Catechols; D009942:Organometallic Compounds; D010422:Pentanones; D014011:Tinidazole; D004917:Erythromycin; D000658:Amoxicillin; C057364:nitecapone; D013752:Tetracycline; C002791:bismuth tripotassium dicitrate; D015232:Dinoprostone